PHASE IB STUDY OF SELICRELUMAB (CD40 AGONIST) IN COMBINATION WITH ATEZOLIZUMAB (ANTI-PD-L1) IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：8
|
作者：
Barlesi, Fabrice [1 ]
Lolkema, Martijn [2 ]
Rohrberg, Kristoffer Staal [3 ]
Hierro, Cinta [4 ]
Marabelle, Aurelien [5 ]
Razak, Albiruni Abdul [6 ]
Teixeira, Luis [7 ]
Boni, Valentina [8 ]
Miller, Wilson H. [9 ]
Aggarwal, Charu [10 ]
Stern, Martin [11 ]
Cirovic, Olivera [12 ]
Cirovic, Olivera [12 ]
Romagnoli, Barbara [12 ]
Christen, Randolph [12 ]
Dodia, Raksha [13 ]
Smart, Kevin [13 ]
Reis, Bernhard [12 ]
Staedler, Nicolas [11 ]
Watson, Carl [14 ]
Steeghs, Neeltje [15 ]
机构：
[1] Gustave Roussy Canc Campus, Villejuif, France
[2] Erasmus MC Canc Inst, Rotterdam, Netherlands
[3] Rigshosp, Copenhagen, Denmark
[4] Vall dHebron Univ Hosp, Barcelona, Spain
[5] Univ Paris Saclay, Gustave Roussy, Villejuif, France
[6] Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] St Louis Hosp, AP HP, Paris, France
[8] START Madrid, Madrid, Spain
[9] Jewish Gen Hosp, Montreal, PQ, Canada
[10] Univ Penn, Philadelphia, PA 19104 USA
[11] Roche Innovat Ctr Zurich, Schlieren, Switzerland
[12] Roche Innovat Ctr Basel, Basel, Switzerland
[13] Roche Innovat Ctr Welwyn, Welwyn Garden City, Herts, England
[14] A4P Consulting Ltd, Sandwich, Kent, England
[15] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0291
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
291
引用
收藏
页码：A178 / A178
页数：1
相关论文
共 50 条
  • [41] A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors
    Rosen, Peter J.
    Sweeney, Christopher J.
    Park, Dorothy J.
    Beaupre, Darrin M.
    Deng, Hongjie
    Leitch, Ian M.
    Shubhakar, Poornima
    Zhu, Min
    Oliner, Kelly S.
    Anderson, Abraham
    Yee, Lorrin K.
    CLINICAL CANCER RESEARCH, 2010, 16 (09) : 2677 - 2687
  • [42] Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors
    Tolcher, Anthony W.
    Sznol, Mario
    Hu-Lieskovan, Siwen
    Papadopoulos, Kyriakos P.
    Patnaik, Amita
    Rasco, Drew W.
    Di Gravio, Donna
    Huang, Bo
    Gambhire, Dhiraj
    Chen, Ying
    Pathan, Nuzhat
    Wang, Kai
    Schmidt, Emmett V.
    Chow, Laura Quan Man
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors
    Carneiro, Benedito A.
    Jotte, Robert M.
    Gabrail, Nashat Y.
    Wentzel, Kristopher
    Huang, Funan
    Chaturvedi, Shalini
    Weispfenning, Anke
    Hiemeyer, Florian
    Morcos, Peter N.
    Soler, Lidia Mongay
    Childs, Barrett H.
    Hansen, Aaron R.
    CANCER RESEARCH COMMUNICATIONS, 2025, 5 (03): : 444 - 457
  • [44] Safety and efficacy of copanlisib in combination with nivolumab: A phase Ib study in patients with advanced solid tumors
    Carneiro, Benedito A.
    Jotte, Robert
    Gabrail, Nashat
    Hamid, Omid
    Huang, Funan
    Chaturvedi, Shalini
    Herpers, Matthias
    Soler, Lidia Mongay
    Childs, Barrett H.
    Hansen, Aaron
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [45] Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma
    Tang, Bixia
    Xiao, Jun
    Chi, Zhihong
    Duan, Rong
    Cui, Chuanliang
    Si, Lu
    Liu, Yixun
    Hu, Xuechun
    Liu, Zhi
    Xiang, Ping
    Li, Siming
    Yan, Xieqiao
    Zhou, Li
    Li, Juan
    Li, Yujie
    Yu, Xiaohui
    Dai, Xiangrong
    Li, Xiaoyi
    Guo, Jun
    Sheng, Xinan
    ONCOLOGIST, 2024,
  • [46] A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors
    Burris, Howard A.
    Gordon, Michael S.
    Hellmann, Matthew David
    LoRusso, Patricia
    Emens, Leisha A.
    Hodi, F. Stephen
    Lieu, Christopher Hanyoung
    Infante, Jeffrey R.
    Tsai, Frank Yung-Chin
    Eder, Joseph Paul
    Cleary, James M.
    Jelovac, Danijela
    Tsuhako, Amy L.
    Mueller, Lars
    Lin, Ray
    Morrissey, Kari
    Mahrus, Sami
    Morley, Roland
    Pirzkall, Andrea
    Davis, Sarah Lindsey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232
    Villa-Ruano, Nemesio
    Guerrero-Gonzalez, Tayde
    Gomez-Conde, Eduardo
    Perez-Santos, Martin
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2020, 30 (10) : 723 - 727
  • [48] A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors
    Deva, S.
    Lee, J-S.
    Lin, C-C.
    Yen, C-J.
    Millward, M.
    Chao, Y.
    Keam, B.
    Jameson, M.
    Hou, M-M.
    Kang, Y-K.
    Markman, B.
    Lu, C-H.
    Rau, K-M.
    Lee, K-H.
    Horvath, L.
    Friedlander, M.
    Hill, A.
    Wu, J.
    Hou, J.
    Desai, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas
    Coyne, Geraldine O'Sullivan
    Yap, Timothy A.
    Moore, Nancy
    Mittra, Arjun
    Takebe, Naoko
    Juwara, Lamin
    Khan, Sabrina
    Dumbrava, Ecaterina Ileana
    Streicher, Howard
    Piekarz, Richard
    Sharon, Elad
    Meric-Bernstam, Funda
    Parchment, Ralph
    Navas, Tony
    Fung, King Leung
    Mitchell, James
    Fino, Kristin
    Montez, Sandra
    Doyle, Austin
    Rubinstein, Laurence
    Doroshow, James H.
    Chen, Alice P.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [50] A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors.
    Lutzky, Jose
    Antonia, Scott Joseph
    Blake-Haskins, Andy
    Li, Xia
    Robbins, Paul B.
    Shaiabl, Aiman M.
    Vasseill, Jim
    Ibrahim, Ramy A.
    Khleif, Samir
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345